Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials
Pooled result · Overall cancerResult — go to the resultRelative risk 1.03 95% CI 0.96–1.10Authors' conclusion
SGLT2 inhibitors are not associated with an increased risk of cancer outcomes, providing reassuring data regarding previous safety concerns.
Study context
- Population
- Adults in RCTs of SGLT2 inhibitors with ≥48 weeks follow-up; PubMed, Embase and CENTRAL searched up to June 20th, 2022
- Participants
- 116,375 adults76 RCTs
- Comparison
- SGLT2 inhibitors vs comparator
- Outcome
- Overall risk of cancer
Methodological detailsRoB 2.0 risk of bias, GRADE quality of evidence, trial sequential analysis, minimum follow-up 48 weeks, Overall risk of bias was low
- RoB 2.0 risk of bias
- GRADE quality of evidence
- Trial sequential analysis
- Minimum follow-up 48 weeks
- Overall risk of bias was low
Pooled result
Overall cancer
Relative risk
1.03
95% CI 0.96–1.10
SGLT2 inhibitorsvs comparator
RR 1.03 (95% CI 0.96–1.10)
As reported in the abstract
Further pooled results
Cancer mortality
| RR (95% CI) | ||
|---|---|---|
| SGLT2 inhibitors | 0.99 (0.85–1.16) | |
| 0.512Relative risk (log scale) |
Breast cancer
| RR (95% CI) | ||
|---|---|---|
| SGLT2 inhibitorsLikely little to no difference | 1.01 (0.77–1.32) | |
| 0.512Relative risk (log scale) |
Bladder cancer
| RR (95% CI) | ||
|---|---|---|
| SGLT2 inhibitorsLikely little to no difference | 0.93 (0.71–1.21) | |
| 0.512Relative risk (log scale) |
Trial sequential analysis
- Sample size sufficient to avoid missing alternative results
Original publication
Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: A systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. Published 13 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →